NCT05205356

VIGOR: Virtual Genome Center for Infant Health

Active, Not Recruiting
Not specifiedAges 0–99Observational
Boston Children's Hospital
~631 participants
Updated 2026-07-10 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Implementation of VIGOR
Measured over 4 year
Genetics Disease
Genetics/Birth Defects
Genetic Predisposition to Disease
10 sites across 5 states
Texas4
Massachusetts3
Alabama1
Florida1
New Jersey1
  • Timothy Yu, MD, PhD · PRINCIPAL_INVESTIGATOR · Boston Children's Hospital

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Newborns presenting with probable genetic conditions inpatient on the NICU. These may include (but is not limited to) those with unexplained hypotonia, seizures, metabolic disorders, disorders of sex development, interstitial lung disease, immunodeficiency or multiple congenital anomalies.
Babies must have at least one biologic parent available for consent and participation.

Exclusion

Presence of a likely nongenetic explanation for the phenotype (e.g., perinatal asphyxia explained by uterine rupture or placental pathology;
Clinical features pathognomonic for a recognizable chromosomal abnormality, such as trisomy 21;
Associations already known to have low genetic diagnostic yield, including VATER/VACTERL association and OEIS complex;
Infants who die before enrollment;
Known family history of genetic disease that is plausibly the cause of the infant's illness; - Those with a prenatal genetic diagnosis.
  • Implementation of VIGOR4 year

    Penetration of VIGOR measured by percentage of eligible participants who were enrolled, tested, providers received CIR and completed a disclosure session.